Tu1246 The Effect of Eupatillin on Indomethacin Induced Small Intestinal Injury and Intestinal Permeability

Abstract

Background: Eupatilin has pronounced antiinflammatory activities and exhibits cytoprotective effects in acute gastric injury model. Here we would like to investigate the possible role of protective effects on small intestine in indomethacin induced small intestinal damage model and their effect on intestinal permeability. Methods: Small intestinal damage was induced with indomethacin (15mg/kg). Rats in the treatment group received eupatilin (30 mg/kg) from day 0 to 3, and indomethacin from day 1 to 2 through intragastric lavage. On the contrary, rats in the control group received indomethacin only from day 1 to 2. On the fourth day, Rats were sacrificed, and small intestine was examined to compare the severity of inflammation in both groups by H&E stain. Intestinal permeability was evaluated by Fluorescein isothiocyanate (FITC)-labeled dextran. Western blot was performed to comfirm the association of eupatillin with ERK pathway in the prevention of small intestinal injury. Results: The inflammation score in the Eupatilin group was low compared with that in the indomethacin only group. Intestinal permeability evaluated by Fluorescein isothiocyanate(FITC)-labeled dextran was low in Eupatilin group compared to indomethacin only group(16204.2±13832.1 vs 30403.7±24012.6 , p value <0.05). Western blots revealed eupatilin enhanced the phosphorylation of extracellular signal-regulated kinase (p-ERK) expression in small bowel mucosa. Conclusion: Eupatilin is effective in the prevention of intestinal mucosal injury and prevents the increase of intestinal permeability by enhancing restitution of RIE cells via ERK activation.